

FIGURE 1

The flowchart illustrates the system architecture for converting stenographic symbols into HTML. It consists of the following components and steps:

- 1** **Stenographic Writing Device - Phonetic Symbols** (labeled 106): The source of the stenographic symbols.
- 2** **RS232-RS232 Connection**: The connection between the writing device and the translation software.
- 3** **Computer Assisted Translation Software Program** (labeled 108): The program that translates the phonetic symbols into English text.
- 4** **RS232-RS232 Connection**: The connection between the translation software and the text sender.
- 5** **IDEAM TextSender** (labeled 110): The component that parses the English text into paragraphs and transmits it to the text receiver.
- 6** **TCP Port Port 7000**: The port used for communication between the text sender and the text receiver.
- 7** **Internet**: The network through which the text is transmitted.
- 8** **IDEAM TextReceiver** (labeled 112): The component that receives the text, converts it into HTML in real-time, and writes it.
- 9** **Server Storage for Presentation Text converted into HTML** (labeled 114): The storage for the converted HTML text.

FIGURE 2




FIGURE 3

096803-112004




FIGURE 4 (browser screenshot)




FIGURE 5 (Browser Screen shot)

FILE EDIT

⬅ ➡ ✕ ↶

Onyx Pharmaceuticals (ONXX) President Hollings - 11/21/00 — 402

Additional Text Not Available — 404

405 - Introduction: Renton discusses the company's treatment for cancer. He says this technology modifies the virus by killing tumor cells and not healthy cells. He is hopeful to extend the treatment beyond head and neck cancers.

Bill: Shares of biotech firm Onyx Pharmaceuticals continue to climb for the second day in a row on positive news about an experimental drug that appears to help shrink head and neck tumors. The latest research shows the drug Onyx-15 is working on tumors that failed to respond to other therapies. Joining me now to talk about the development is Hollings Renton, CEO of Onyx Pharmaceuticals. He's in sunny and warm, Palm Springs, California. How have you been? It is nice to see you again.

410 { It is nice to you see you, Bill.

Bill: Tell me about the latest developments and where are you in the latest trials at this point?

Hollings: What we just published in cancer research this week is in the end-stage patients with head and neck cancer we were able to shrink 50% of the injected tumors in 20% of the patients in the study.

Bill: Describe very briefly how this works.

Hollings: This technology sets Onyx apart from all other cancer therapy companies in that we are able to modify a virus, so it only replicates and kills tumor cells and does not damage normal cells.

406 }

LEAF 1

FIGURE 6